Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Harvoni
Pharma
Gilead’s hep C generics now own more than 20% of market
Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.
Angus Liu
Sep 16, 2019 11:34am
Longtime Gilead CFO Washington set to retire
May 1, 2019 12:01pm
Despite 35 price hikes, Sanofi’s net prices fell again in 2018
Feb 21, 2019 8:12am
SCOTUS rebuffs Gilead, Merck appeals in high-profile battles
Jan 8, 2019 10:30am
The 20 most expensive retail drugs in 2018
Dec 28, 2018 11:30am
AbbVie inks deal to boost Mavyret access in nearly 100 countries
Nov 13, 2018 11:40am
